David Bigler, MD
MOHS-Micrographic Surgery · Lincoln, NENPI 1740398320
Payments from drug & device makers
Across 349 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$822
- Sanofi$776
- Johnson & Johnson$712
- Lilly USA, LLC$640
- Novartis$520
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,76091%
- Education$6479%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 100 | $1,965 |
| Sun Pharmaceutical Industries Inc. | 32 | $822 |
| Sanofi | 26 | $776 |
| Johnson & Johnson | 26 | $712 |
| Lilly USA, LLC | 36 | $640 |
| Novartis | 26 | $520 |
| Regeneron Healthcare Solutions, Inc. | 18 | $460 |
| E.r. Squibb & Sons, L.L.C. | 18 | $258 |
| Amgen | 12 | $244 |
| UCB, Inc. | 10 | $195 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 9 | $137 |
| LEO Pharma Inc. | 5 | $115 |
| Galderma Laboratories, L.p. | 6 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Dermira, Inc. | 3 | $68 |
| Pfizer | 4 | $61 |
| DUSA Pharmaceuticals, Inc. | 3 | $54 |
| Bristol Myers Squibb | 3 | $53 |
| Genentech USA, Inc. | 2 | $26 |
| VYNE Pharmaceuticals Inc. | 1 | $24 |
| Arcutis Biotherapeutics, Inc. | 1 | $23 |
| Convatec Inc. | 1 | $21 |
| Organon | 3 | $17 |
| Dermavant Sciences, Inc. | 1 | $16 |
| Almirall LLC | 1 | $15 |
| Promius Pharma LLC | 1 | $13 |
How this compares
Too few mohs-micrographic surgery providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 280 | $2,212 |
| Calcipotriene | 15 | $2,067 |
| CiclopiroxCiclopirox Olamine | 87 | $1,416 |
| Minocycline Hcl | 32 | $1,412 |
| Gentamicin Sulfate | 33 | $1,166 |
| Triamcinolone Acetonide | 149 | $1,156 |
| Cefdinir | 24 | $936 |
| Cephalexin | 94 | $781 |
| Ketoconazole | 35 | $649 |
| Clindamycin Phosphate | 22 | $621 |
| Ciprofloxacin Hcl | 20 | $171 |
| Hydrocortisone | 13 | $74 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Lincoln
- Tomas HuertaOmaha$6K
- Anthony GriessOmaha$348
- Kendra LesiakOmaha$273
- David WattsOmaha$234
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.